🇺🇸 FDA
Patent

US 12145925

Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

granted A61PA61P35/00

Quick answer

US patent 12145925 (Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer) held by The Regents of the University of California expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61P, A61P35/00